Cargando…
Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines
Several live-attenuated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of live-attenuated vi...
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Ltd.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563577/ https://www.ncbi.nlm.nih.gov/pubmed/33070999 http://dx.doi.org/10.1016/j.vaccine.2020.09.042 |
| _version_ | 1783595521526464512 |
|---|---|
| author | Gurwith, Marc Condit, Richard C. Excler, Jean-Louis Robertson, James S. Kim, Denny Fast, Patricia E. Drew, Stephen Wood, David Klug, Bettina Whelan, Mike Mallett Moore, Tamala Khuri-Bulos, Najwa Smith, Emily R. Chen, Robert T Kochhar, Sonali |
| author_facet | Gurwith, Marc Condit, Richard C. Excler, Jean-Louis Robertson, James S. Kim, Denny Fast, Patricia E. Drew, Stephen Wood, David Klug, Bettina Whelan, Mike Mallett Moore, Tamala Khuri-Bulos, Najwa Smith, Emily R. Chen, Robert T Kochhar, Sonali |
| author_sort | Gurwith, Marc |
| collection | PubMed |
| description | Several live-attenuated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of live-attenuated viral vaccines. This will help key stakeholders assess potential safety issues and understand the benefit-risk of such vaccines. The standardized and structured assessment provided by the template would also help to contribute to improved communication and support public acceptance of licensed live-attenuated viral vaccines. |
| format | Online Article Text |
| id | pubmed-7563577 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-75635772020-10-16 Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines Gurwith, Marc Condit, Richard C. Excler, Jean-Louis Robertson, James S. Kim, Denny Fast, Patricia E. Drew, Stephen Wood, David Klug, Bettina Whelan, Mike Mallett Moore, Tamala Khuri-Bulos, Najwa Smith, Emily R. Chen, Robert T Kochhar, Sonali Vaccine Review Several live-attenuated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of live-attenuated viral vaccines. This will help key stakeholders assess potential safety issues and understand the benefit-risk of such vaccines. The standardized and structured assessment provided by the template would also help to contribute to improved communication and support public acceptance of licensed live-attenuated viral vaccines. Published by Elsevier Ltd. 2020-11-17 2020-10-16 /pmc/articles/PMC7563577/ /pubmed/33070999 http://dx.doi.org/10.1016/j.vaccine.2020.09.042 Text en © 2021 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Review Gurwith, Marc Condit, Richard C. Excler, Jean-Louis Robertson, James S. Kim, Denny Fast, Patricia E. Drew, Stephen Wood, David Klug, Bettina Whelan, Mike Mallett Moore, Tamala Khuri-Bulos, Najwa Smith, Emily R. Chen, Robert T Kochhar, Sonali Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines |
| title | Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines |
| title_full | Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines |
| title_fullStr | Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines |
| title_full_unstemmed | Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines |
| title_short | Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines |
| title_sort | brighton collaboration viral vector vaccines safety working group (v3swg) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines |
| topic | Review |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563577/ https://www.ncbi.nlm.nih.gov/pubmed/33070999 http://dx.doi.org/10.1016/j.vaccine.2020.09.042 |
| work_keys_str_mv | AT gurwithmarc brightoncollaborationviralvectorvaccinessafetyworkinggroupv3swgstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofliveattenuatedviralvaccines AT conditrichardc brightoncollaborationviralvectorvaccinessafetyworkinggroupv3swgstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofliveattenuatedviralvaccines AT exclerjeanlouis brightoncollaborationviralvectorvaccinessafetyworkinggroupv3swgstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofliveattenuatedviralvaccines AT robertsonjamess brightoncollaborationviralvectorvaccinessafetyworkinggroupv3swgstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofliveattenuatedviralvaccines AT kimdenny brightoncollaborationviralvectorvaccinessafetyworkinggroupv3swgstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofliveattenuatedviralvaccines AT fastpatriciae brightoncollaborationviralvectorvaccinessafetyworkinggroupv3swgstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofliveattenuatedviralvaccines AT drewstephen brightoncollaborationviralvectorvaccinessafetyworkinggroupv3swgstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofliveattenuatedviralvaccines AT wooddavid brightoncollaborationviralvectorvaccinessafetyworkinggroupv3swgstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofliveattenuatedviralvaccines AT klugbettina brightoncollaborationviralvectorvaccinessafetyworkinggroupv3swgstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofliveattenuatedviralvaccines AT whelanmike brightoncollaborationviralvectorvaccinessafetyworkinggroupv3swgstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofliveattenuatedviralvaccines AT mallettmooretamala brightoncollaborationviralvectorvaccinessafetyworkinggroupv3swgstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofliveattenuatedviralvaccines AT khuribulosnajwa brightoncollaborationviralvectorvaccinessafetyworkinggroupv3swgstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofliveattenuatedviralvaccines AT smithemilyr brightoncollaborationviralvectorvaccinessafetyworkinggroupv3swgstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofliveattenuatedviralvaccines AT chenrobertt brightoncollaborationviralvectorvaccinessafetyworkinggroupv3swgstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofliveattenuatedviralvaccines AT kochharsonali brightoncollaborationviralvectorvaccinessafetyworkinggroupv3swgstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofliveattenuatedviralvaccines AT brightoncollaborationviralvectorvaccinessafetyworkinggroupv3swgstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofliveattenuatedviralvaccines |